Stage FocusSeed, Series A
GeographyUS, Europe
TypeVC
Last Activity2025
Industry Focus
Industries
Biotech
Technical BenchStrong
Investor TypeDeepTech Specialist
ExposureMostly DeepTech Investments
Bio
SR One was founded in 1985 as GSK's corporate venture arm and spun out as an independent firm in 2020. Fund I raised $500M (2020), followed by Fund II at $600M (2023). The focus is early-stage biotech — translating groundbreaking science into next-generation medicines.
The firm operates from San Francisco and London with a trans-Atlantic presence. Notable portfolio companies include CRISPR Therap...
Notable Investments
C
CRISPR TherapeuticsP
Principia BiopharmaT
Turning Point TherapeuticsN
NkartaSimilar Funds
4BIO Capital
Geneva, Switzerland
DeepTech NativeBiotechSeedSeries A
Abingworth
London, United Kingdom
DeepTech NativeBiotechMedTechSeedSeries A
Brandon Capital
Melbourne, Australia
DeepTech NativeBiotechMedTechSeedSeries A
Leaps by Bayer
Leverkusen, Germany
DeepTech NativeBiotechAgriTechMedTechSeedSeries A
M Ventures (Merck)
Amsterdam, Netherlands
DeepTech NativeBiotechSemiconductorsAdvanced MaterialsSeedSeries A
Medicxi
Basel, Switzerland
DeepTech NativeBiotechSeedSeries A